Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Cited by (999)

Items 101–200 of 999

1. Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo
   Nina R. Derby, Manjari Lal, Meropi Aravantinou, Larisa Kizima, Patrick Barnable, Aixa Rodríguez, Manshun Lai, Asa Wesenberg, Shweta R. Ugaonkar, Keith Levendosky et al. · 2018 · Nature Communications
2. Fifty Years in Search of Selective Antiviral Drugs
   Erik De Clercq · 2019 · Journal of Medicinal Chemistry
3. Ultra-long-acting removable drug delivery system for HIV treatment and prevention
   Martina Kovářová, S. Rahima Benhabbour, Ivana Massud, Rae Ann Spagnuolo, Brianna L Skinner, Caroline Baker, Craig Sykes, Katie R. Mollan, Angela D. M. Kashuba, Jose Gerardo Garcia-Lerma et al. · 2018 · Nature Communications
4. Poor medication adherence in clinical trials: consequences and solutions
   Alasdair M. Breckenridge, Jeffrey K Aronson, Terrence F. Blaschke, Dan Hartman, Carl C. Peck, Bernard Vrijens · 2017 · Nature Reviews Drug Discovery
5. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
   Raymond A. Tetteh, Barbara A Yankey, Edmund Tetteh Nartey, Margaret Yaa Lartey, Hubert G. M. Leufkens, Alexander Dodoo · 2017 · Drug Safety
6. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020
   Mary R. Tanner, Peter Miele, Wendy Carter, Sheila Salvant Valentine, Richard Louis Dunville, Bill G. Kapogiannis, Dawn K. Smith · 2020 · MMWR Recommendations and Reports
7. Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city
   Matthew F. Garnett, Yael Hirsch‐Moverman, Julie C. Franks, Eleanor Hayes‐Larson, Wafaa El‐Sadr, Sharon Mannheimer · 2017 · AIDS Care
8. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial
   Jessica Elizabeth Haberer, Elizabeth Anne Bukusi, Nelly Mugo, Maria N. Pyra, Catherine Kiptinness, Kevin Oware, Lindsey E. Garrison, Katherine K. Thomas, Nicholas Musinguzi, Susan A. Morrison et al. · 2021 · The Lancet HIV
9. HIV pre-exposure prophylaxis for women
   Anandi N. Sheth, Charlotte-Paige Rolle, Monica Gandhi · 2016 · Journal of Virus Eradication
10. Multipurpose prevention technologies: the future of HIV and STI protection
    José A. Fernández-Romero, Carolyn D. Deal, Betsy C. Herold, John T. Schiller, Dorothy L. Patton, Thomas M. Zydowsky, Joe Romano, Christopher D. Petro, Manjulaa Narasimhan · 2015 · Trends in Microbiology
11. What people want from sex and preexposure prophylaxis
    Robert M. Grant, Kimberly A. Koester · 2015 · Current Opinion in HIV and AIDS
12. Stated product formulation preferences for HIV pre‐exposure prophylaxis among women in the VOICE‐D (MTN‐003D) study
    Ellen H. Luecke, Helen Cheng, Kubashni Woeber, Teopista Nakyanzi, Imelda C. Mahaka, Ariane van der Straten, on behalf of the MTN‐003D Study Team · 2016 · Journal of the International AIDS Society
13. Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012–2017
    Ya-Lin A. Huang, Guoyu Tao, Dawn K. Smith, Karen W. Hoover · 2020 · Clinical Infectious Diseases
14. HIV-Related Mistrust (or HIV Conspiracy Theories) and Willingness to Use PrEP Among Black Women in the United States
    Bisola O. Ojikutu, Ndidiamaka Amutah‐Onukagha, Taylor F. Mahoney, C. Tibbitt, Sannisha K. Dale, Kenneth Hugh Mayer, Laura M. Bogart · 2020 · AIDS and Behavior
15. Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects
    Marcela Krečmerová, Pavel Majer, Rana Rais, Barbara Stauch Slusher · 2022 · Frontiers in Chemistry
16. Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
    Leah M. Johnson, Sai Archana Krovi, Linying Li, Natalie Girouard, Zach R. Demkovich, Daniel Myers, Ben Creelman, Ariane van der Straten · 2019 · Pharmaceutics
17. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women
    Jeanne Marisa Marrazzo, Tao Li, Marissa Becker, Ashley A. Leech, Allan W. Taylor, Faith Ussery, Michael Kiragu, Sushena Reza‐Paul, Janet J. Myers, Linda‐Gail Bekker et al. · 2024 · JAMA
18. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State
    Sharon M. Seifert, Xinhui Chen, Amie L. Meditz, José Castillo‐Mancilla, Edward M. Gardner, Julie A. Predhomme, Carolyn Clayton, Gregory L. Austin, Brent E. Palmer, Jia‐Hua Zheng et al. · 2016 · AIDS Research and Human Retroviruses
19. HIV and women in the USA: what we know and where to go from here
    Adaora A. Adimora, Catalina B. Ramirez, Tonia Poteat, Nancie M. Archin, Dawn Averitt, Judith D. Auerbach, Allison Lorna Agwu, Judith S. Currier, Monica Gandhi · 2021 · The Lancet
20. Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting
    Madeline C. Montgomery, Catherine E. Oldenburg, Amy Stewart Nunn, Leandro Antonio Mena, Peter L. Anderson, Teri J. Liegler, Kenneth Hugh Mayer, Rupa R. Patel, Alexi A Almonte, Philip A. Chan · 2016 · PLoS ONE
21. Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa
    Robyn Eakle, Adam H. Bourne, Judie Mbogua, Nyaradzo Mutanha, Helen Rees · 2018 · Journal of the International AIDS Society
22. Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California
    Matthew R. Beymer, Michelle A. DeVost, Robert E. Weiss, Rhodri Dierst-Davies, Chelsea L. Shover, Raphael J. Landovitz, Corinne Beniasians, Ali J. Talan, Risa P. Flynn, Robyn C. Krysiak et al. · 2018 · Sexually Transmitted Infections
23. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions
    Ioannis Hodges-Mameletzis, Virginia A. Fonner, Shona Dalal, Nelly Mugo, Busisiwe Msimanga-Radebe, Rachel Clare Baggaley · 2019 · Drugs
24. Motives for choosing, switching and stopping daily or event‐driven pre‐exposure prophylaxis – a qualitative analysis
    Hanne M. L. Zimmermann, Sanne W Eekman, Roel Achterbergh, Maarten F. Schim van der Loeff, Maria Prins, Henry J.C. de Vries, Elske Hoornenborg, Udi Davidovich · 2019 · Journal of the International AIDS Society
25. Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission
    Kovarova, Martina, Council, Olivia D., Date, Abhijit A., Long, Julie M., Nochii, Tomonori, Belshan, Michael, Shibata, Annemarie, Vincent, Heather, Baker, Caroline E., Thayer, William O. et al. · 2015 · PLOS Pathogens
26. Alcohol consumption, substance use, and depression in relation to HIV Pre-Exposure Prophylaxis (PrEP) nonadherence among gay, bisexual, and other men-who-have-sex-with-men
    Paul A. Shuper, Narges Joharchi, Isaac I. Bogoch, Mona Rafik Loutfy, Frederic Crouzat, Philippe El‐Helou, David C. Knox, Kevin Woodward, Jürgen T. Rehm · 2020 · BMC Public Health
27. Impact of cocaine abuse on HIV pathogenesis
    Dash, Sabyasachi, Balasubramaniam, Muthukumar, Villalta, Fernando, Dash, Chandravanu, Pandhare, Jui · 2015 · Frontiers in Microbiology
28. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study
    Monica Gandhi, David V. Glidden, Kenneth Hugh Mayer, Mauro Schechter, Susan Buchbinder, Beatriz Gilda Jegerhorn Grinsztejn, Sybil Hosek, Martín Casapía, Juan V. Guanira, Linda‐Gail Bekker et al. · 2016 · The Lancet HIV
29. Disclosure of pharmacokinetic drug results to understand nonadherence
    Ariane van der Straten, Elizabeth Montgomery, Petina Musara, Juliane Etima, Sarita Naidoo, Nicole D. Laborde, Miriam Hartmann, Lisa Levy, Thola Bennie, Helen Cheng et al. · 2015 · AIDS
30. The Potential of Pre-Exposure Prophylaxis for Women in Violent Relationships
    Amy Braksmajer, Theresa E. Senn, James M. McMahon · 2016 · AIDS Patient Care and STDs
31. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre‐exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention‐effective adherence
    Jessica Elizabeth Haberer, Lara Kidoguchi, Renee A. Heffron, Nelly Mugo, Elizabeth Anne Bukusi, Elly Tebasoboke Katabira, Stephen B. Asiimwe, Katherine K. Thomas, Connie Celum, Jared M. Baeten · 2017 · Journal of the International AIDS Society
32. Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings
    Monica Gandhi, Guohong Wang, Roger King, Warren C. Rodrigues, Michael Vincent, David V. Glidden, Tim Roy Cressey, Peter Bacchetti, Matthew A. Spinelli, Hideaki Okochi et al. · 2019 · AIDS
33. HIV incidence after pre-exposure prophylaxis initiation among women and men at elevated HIV risk: A population-based study in rural Kenya and Uganda
    Catherine A. Koss, Diane V. Havlir, James Ayieko, Dalsone Kwarisiima, Jane Kabami, Gabriel Chamie, Mucunguzi Atukunda, Yusuf Mwinike, Florence Mwangwa, Asiphas Owaraganise et al. · 2021 · PLoS Medicine
34. HIV-Related Stigma Research as a Priority at the National Institutes of Health
    Gregory L. Greenwood, Amber Wilson, Geetha P. Bansal, Christopher Barnhart, Elizabeth Barr, Rick A. Berzon, Cheryl Anne Boyce, William N. Elwood, Joyonna Gamble‐George, Mary T. Glenshaw et al. · 2021 · AIDS and Behavior
35. How Has HIV Pre-Exposure Prophylaxis (PrEP) Changed Sex? A Review of Research in a New Era of Bio-behavioral HIV Prevention
    Christian Grov, Drew A. Westmoreland, Alexa B. D’Angelo, David W. Pantalone · 2021 · The Journal of Sex Research
36. Uptake of and adherence to oral pre-exposure prophylaxis among adolescent girls and young women at high risk of HIV-infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers
    Ivy Kayesu, Yunia Mayanja, Catherine Nakirijja, Yvonne Wangũi Machira, Matt A. Price, Janet Seeley, Godfrey Siu · 2022 · BMC Women s Health
37. Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial
    Amy L. Corneli, Brian Perry, Kawango E. Agot, Khatija Ahmed, Fulufhelo Malamatsho, Lut Van Damme · 2015 · PLoS ONE
38. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring
    Monica Gandhi, David V. Glidden, Albert Liu, Peter L. Anderson, Howard Horng, Patricia A. Defechereux, Juan V. Guanira, Beatriz Gilda Jegerhorn Grinsztejn, Suwat Chariyalertsak, Linda‐Gail Bekker et al. · 2015 · The Journal of Infectious Diseases
39. Sexually Transmitted Infections: Impact and Cost-Effectiveness of Prevention
    Harrell W. Chesson, Philippe Mayaud, Sevgi O. Aral · 2017 · World Bank, Washington, DC eBooks
40. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial
    Miranda I. Murray, Martin H. Markowitz, Ian Frank, Robert M. Grant, Kenneth Hugh Mayer, Krischan J Hudson, Britt S. Stancil, Susan L. Ford, Parul Patel, Alex R. Rinehart et al. · 2018 · HIV Clinical Trials
41. PrEParing Women to Prevent HIV: An Integrated Theoretical Framework to PrEP Black Women in the United States
    Crystal Chapman Lambert, Jeanne Marisa Marrazzo, K. Rivet Amico, Michael J. Mugavero, Latesha E. Elopre · 2018 · Journal of the Association of Nurses in AIDS Care
42. Age‐disparate sex and HIV risk for young women from 2002 to 2012 in South Africa
    Meredith Evans, Kathryn Risher, Nompumelelo Precious Zungu, Olive Shisana, Sizulu Moyo, David D. Celentano, Brendan Maughan‐Brown, Thomas M Rehle · 2016 · Journal of the International AIDS Society
43. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines
    Edwina Wright, Andrew Edwin Grulich, Katy Roy, Mark Alastair Boyd, Vincent J. Cornelisse, Darren B. Russell, Darryl O’Donnell, Bill Whittaker, Levinia Crooks, Iryna Zablotska · 2017 · Journal of Virus Eradication
44. A molecular tweezer antagonizes seminal amyloids and HIV infection
    Edina Lump, Laura M. Castellano, Christoph Andreas Meier, Janine Seeliger, Nelli Erwin, Benjamin Sperlich, Christina Martina Stürzel, Shariq M. Usmani, Rebecca M. Hammond, Jens von Einem et al. · 2015 · eLife
45. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing
    José Castillo‐Mancilla, Sharon M. Seifert, Kayla M. Campbell, Stacey S. Coleman, Kevin J. McAllister, Jia‐Hua Zheng, Edward M. Gardner, Albert Liu, David V. Glidden, Robert M. Grant et al. · 2016 · Antimicrobial Agents and Chemotherapy
46. Development and in vivo safety assessment of tenofovir-loaded nanoparticles-in-film as a novel vaginal microbicide delivery system
    Alexandra Machado, Cassilda Cunha-Reis, Francisca Araújo, Rute Nunes, Vítor Seabra, Domingos Ferreira, José das Neves, Bruno Filipe Carmelino Cardoso Sarmento · 2016 · Acta Biomaterialia
47. Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence
    Monica Gandhi, Peter Bacchetti, Warren C. Rodrigues, Matthew A. Spinelli, Catherine A. Koss, Paul K. Drain, Jared M. Baeten, Nelly Mugo, Kenneth Ngure, Leslie Z. Benet et al. · 2018 · EClinicalMedicine
48. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy
    Cynthia Woodsong, Jonathon D. S. Holt · 2015 · Advanced Drug Delivery Reviews
49. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy
    Shweta R. Ugaonkar, Asa Wesenberg, Wilk Jolanta, Samantha Seidor, Olga A. Mizenina, Larisa Kizima, Aixa Rodríguez, Shimin Zhang, Keith Levendosky, Jessica Kenney et al. · 2015 · Journal of Controlled Release
50. Digitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm
    Dockendorf, Marissa F., Hansen, Bryan J., Bateman, Kevin P., Moyer, Matthew, Shah, Jyoti K., Shipley, Lisa A. · 2021 · Clinical and Translational Science
51. Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence
    Danielle Giovenco, Katherine Gill, Lauren Fynn, Menna Duyver, Shannon O’Rourke, Ariane van der Straten, Jennifer F. Morton, Connie Celum, Linda‐Gail Bekker · 2021 · PLoS ONE
52. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film
    Katherine E. Bunge, Charlene S. Dezzutti, Lisa Cencia Rohan, Craig W. Hendrix, Mark A. Marzinke, Nicola Richardson‐Harman, Bernard J. Moncla, Bríd Devlin, Leslie A. Meyn, Hans M. L. Spiegel et al. · 2015 · JAIDS Journal of Acquired Immune Deficiency Syndromes
53. Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward
    Ying-Ru Jacqueline Lo, Carissa Ellen Chu, Jintanat Ananworanich, Jean‐Louis Excler, Joseph D. Tucker · 2015 · AIDS Patient Care and STDs
54. Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals
    Matthew R. Beymer, Ian W. Holloway, Craig Pulsipher, Raphael J. Landovitz · 2019 · Current HIV/AIDS Reports
55. The Effect of PrEP on HIV Incidence Among Men Who Have Sex With Men in the Context of Condom Use, Treatment as Prevention, and Seroadaptive Practices
    Michael T. LeVasseur, Neal D. Goldstein, Loni Philip Tabb, Brianne L. Olivieri‐Mui, Seth L. Welles · 2017 · JAIDS Journal of Acquired Immune Deficiency Syndromes
56. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial
    Randolph P. Matthews, Munjal Patel, Stephanie E. Barrett, Liesbeth Haspeslagh, Tom Reynders, Saijuan Zhang, Sylvie Rottey, Adrian P. Goodey, Ryan C. Vargo, Jay A. Grobler et al. · 2021 · Nature Medicine
57. The promises and challenges of pre‐exposure prophylaxis as part of the emerging paradigm of combination HIV prevention
    Carlos F. Cáceres, Florence Koechlin, Pedro Goicochea, Papa‐Salif Sow, Kevin R O'Reilly, Kenneth Hugh Mayer, Peter Godfrey‐Faussett · 2015 · Journal of the International AIDS Society
58. Mucosal effects of tenofovir 1% gel
    Florian Hladik, Adam Burgener, Lamar Ballweber, Raphaël Gottardo, Slim Fourati, James Y. Dai, Mark J. Cameron, Lucia N. Vojtech, Johanna Strobl, Sean M. Hughes et al. · 2015 · eLife
59. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Urvi M. Parikh, John W. Mellors · 2015 · Current Opinion in HIV and AIDS
60. “How I Wish This Thing Was Initiated 100 Years Ago!” Willingness to Take Daily Oral Pre-Exposure Prophylaxis among Men Who Have Sex with Men in Kenya
    Robinson Karuga, Serah Nduta Njenga, Rueben Mulwa, Nduku Kilonzo, Prince Bahati, Kevin O’reilley, Lawrence J. Gelmon, Stephen Mbaabu, Charles Wachihi, George N. Githuka et al. · 2016 · PLoS ONE
61. Pre-exposure prophylaxis for HIV prevention in women: current perspectives
    Charlene A. Flash, Sannisha K. Dale, Douglas Krakower · 2017 · International Journal of Women s Health
62. PrEP as Peri-conception HIV Prevention for Women and Men
    Renee A. Heffron, Jillian C. Pintye, Lynn T. Matthews, Shannon Weber, Nelly Mugo · 2016 · Current HIV/AIDS Reports
63. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes
    Fernando Notario-Pérez, Roberto Ruíz, María-Dolores Veiga · 2017 · Drug Design Development and Therapy
64. Influences on Early Discontinuation and Persistence of Daily Oral PrEP Use Among Kenyan Adolescent Girls and Young Women: A Qualitative Evaluation From a PrEP Implementation Program
    Jillian C. Pintye, Gabrielle O’Malley, John Kinuthia, Felix Abuna, Jaclyn N Escudero, Melissa Latigo Mugambi, Mercy Awuor, Annabell Dollah, Julia C. Dettinger, Pamela K. Kohler et al. · 2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes
65. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial
    Gonasagrie Nair, Connie Celum, Daniel W. Szydlo, Elizabeth R. Brown, Carolyne Agwau Akello, Rita Nakalega, Pippa Macdonald, Gakiema Milan, Thesla Palanee‐Phillips, Krishnaveni Reddy et al. · 2023 · The Lancet HIV
66. Prevalence of actual uptake and willingness to use pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Hong Kong, China
    Zixin Johnson Wang, Joseph T. F. Lau, Yuan Fang, Mary Ip, Danielle L. Gross · 2018 · PLoS ONE
67. Antibody-mediated prevention and treatment of HIV-1 infection
    Henning Gruell, Florian Klein · 2018 · Retrovirology
68. Awareness and Interest in HIV Pre-Exposure Prophylaxis Among Street-Based Female Sex Workers: Results from a US Context
    Catherine A. Tomko, Ju Nyeong Park, Sean T. Allen, Jennifer L. Glick, Noya Galai, Michele R. Decker, Katherine H. A. Footer, Susan G. Sherman · 2019 · AIDS Patient Care and STDs
69. A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques
    Jonathan T. Su, Solange M. Simpson, Samuel Sung, Ewa Bryndza Tfaily, Ronald S. Veazey, Mark A. Marzinke, Jiang Qiu, David Watrous, Lakmini Widanapathirana, Elizabeth Kerry Pearson et al. · 2019 · Antimicrobial Agents and Chemotherapy
70. Using an Intersectional Framework to Understand the Challenges of Adopting Pre-exposure Prophylaxis (PrEP) Among Young Adult Black Women
    Keosha T. Bond, Alana Gunn, Porche M Williams, Noelle R. Leonard · 2021 · Sexuality Research and Social Policy
71. Comparison of subjective and objective adherence measures for preexposure prophylaxis against HIV infection among serodiscordant couples in East Africa
    Nicholas Musinguzi, Collins D. Muganzi, Yap Boum, Allan Ronald, Mark A. Marzinke, Craig W. Hendrix, Connie Celum, Jared M. Baeten, David R. Bangsberg, Jessica Elizabeth Haberer · 2016 · AIDS
72. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre‐exposure prophylaxis
    HC Koenig, Karam Mounzer, Giffin W. Daughtridge, Caroline E. Sloan, Linden Lalley-Chareczko, GS Moorthy, S. Caitlin Conyngham, AF Zuppa, L.J. Montaner, Pablo Tebas · 2017 · HIV Medicine
73. Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States
    Deanna L. Kerrigan, Andrea R. Mantsios, Robert M. Grant, Marty Markowitz, Patricia A. Defechereux, M. La Mar, Sam Wilson Beckham, P. Hammond, David M. Margolis, Miranda I. Murray · 2017 · AIDS and Behavior
74. Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women
    Andrea Ries Thurman, Jill L. Schwartz, Vivian Brache, Meredith R. Clark, Timothy J. McCormick, Neelima Chandra, Mark A. Marzinke, Frank Z. Stanczyk, Charlene S. Dezzutti, Sharon L. Hillier et al. · 2018 · PLoS ONE
75. Conditional Cash Transfers to Increase Retention in PMTCT Care, Antiretroviral Adherence, and Postpartum Virological Suppression: A Randomized Controlled Trial
    Marcel Yotebieng, Harsha Thirumurthy, Kathryn Elizabeth Moracco, Andrew Edmonds, Martine Tabala, Bienvenu Kawende, Landry Kipula Wenzi, Emile Wemakoy Okitolonda, Frieda Behets · 2016 · JAIDS Journal of Acquired Immune Deficiency Syndromes
76. A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective
    Jennifer L. Bailey, Suzanne Molino, Ana D Vega, Melissa E. Badowski · 2017 · Infectious Diseases and Therapy
77. Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women’s Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States
    Morgan Mari Philbin, Carrigan Leigh Parish, Elizabeth N. Kinnard, Sarah E. Reed, Deanna L. Kerrigan, Maria Luisa Alcaide, Mardge H. Cohen, Oluwakemi Sosanya, Anandi N. Sheth, Adaora A. Adimora et al. · 2020 · AIDS and Behavior
78. Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies
    Sarah E. Rutstein, Dawn K. Smith, Shona Dalal, Rachel Clare Baggaley, Myron S. Cohen · 2020 · The Lancet HIV
79. Relationship dynamics and anticipated stigma: Key considerations for PrEP use among Tanzanian adolescent girls and young women and male partners
    Nrupa Jani, Sanyukta Mathur, Catherine Kahabuka, Neema Makyao, Nanlesta A. Pilgrim · 2021 · PLoS ONE
80. Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions
    Manale Harfouche, Farah Marwan Abu-Hijleh, Charlotte R. James, Katharine Jane Looker, Laith Jamal Abu-Raddad · 2021 · EClinicalMedicine
81. Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues
    Mackenzie Leigh Cottrell, Katy L. Garrett, Heather M. A. Prince, Craig Sykes, Amanda P. Schauer, Cindi W. Emerson, Anne F. Peery, James F. Rooney, Scott H. McCallister, Cynthia L. Gay et al. · 2017 · Journal of Antimicrobial Chemotherapy
82. Acceptability of a long‐acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)
    Elizabeth E. Tolley, Sue Li, Sahar Z. Zangeneh, Millicent Atujuna, Petina Musara, Jessica E. Justman, Subash Pathak, Linda‐Gail Bekker, Shobha Swaminathan, Jill Stanton et al. · 2019 · Journal of the International AIDS Society
83. Empowering adolescent girls in Sub‐Saharan Africa to prevent unintended pregnancy and HIV: A critical research gap
    Phillips, Sharon J., Mbizvo, Michael T. · 2016 · International Journal of Gynecology & Obstetrics
84. Primary HIV-1 infection in users of pre-exposure prophylaxis
    Juan Ambrosioni, Elisa Petit, Geoffroy Liégeon, Montserrat Laguno, José María Miró · 2020 · The Lancet HIV
85. Nanomedicine in the development of anti-HIV microbicides
    José das Neves, Rute Nunes, Francisca Rodrigues, Bruno Filipe Carmelino Cardoso Sarmento · 2016 · Advanced Drug Delivery Reviews
86. Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension
    David V. Glidden, K. Rivet Amico, Albert Liu, Sybil Hosek, Peter L. Anderson, Susan Buchbinder, Vanessa McMahan, Kenneth Hugh Mayer, Burns David, Mauro Schechter et al. · 2016 · Clinical Infectious Diseases
87. Early antiretroviral therapy and daily pre‐exposure prophylaxis for HIV prevention among female sex workers in Cotonou, Benin: a prospective observational demonstration study
    Aminata Mboup, Luc Béhanzin, Fernand Aimé Guédou, Nassirou Geraldo, Ella Goma‐Matsétsé, Katia Giguère, Marlène Aza‐Gnandji, Léon Kessou, Mamadou Diallo, René Kpèmahouton Kêkê et al. · 2018 · Journal of the International AIDS Society
88. End‐user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study
    Elizabeth Montgomery, Mags E. Beksinska, Nyaradzo Mavis Mgodi, Jill L. Schwartz, Rachel Weinrib, Erica N. Browne, Nonhlanhla Mphili, Petina Musara, Manjeetha Jaggernath, Susan Ju et al. · 2019 · Journal of the International AIDS Society
89. Development of parallel measures to assess HIV stigma and discrimination among people living with HIV, community members and health workers in the HPTN 071 (PopART) trial in Zambia and South Africa
    Anne L. Stangl, Pamela S. Lilleston, Hlengani Mathema, Triantafyllos Pliakas, Shari Krishnaratne, Kirsty M. Sievwright, Nomhle Bell‐Mandla, Redwaan Vermaak, Tila Mainga, Mara C. Steinhaus et al. · 2019 · Journal of the International AIDS Society
90. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study
    Jenna Yager, José Castillo‐Mancilla, Mustafa E. Ibrahim, Kristina M. Brooks, Cricket McHugh, Mary Morrow, Scott H. McCallister, Lane R. Bushman, Samantha MaWhinney, Jennifer J. Kiser et al. · 2020 · JAIDS Journal of Acquired Immune Deficiency Syndromes
91. The Pharmacist's Expanding Role in HIV Pre-Exposure Prophylaxis
    Eric K. Farmer, David E. Koren, Agnes Cha, Katlyn Grossman, Drew W. Cates · 2019 · AIDS Patient Care and STDs
92. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants’ Explanations for Dishonesty
    Elizabeth Montgomery, Barbara Mensch, Petina Musara, M. Hartmann, Kubashni Woeber, Juliane Etima, Ariane van der Straten · 2016 · AIDS and Behavior
93. Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value
    Andrew Max Abaasa, Craig W. Hendrix, Monica Gandhi, Peter L. Anderson, Anatoli Kamali, Freddie Kibengo, Eduard Joachim Sanders, Gaudensia Nzembi Mutua, Namandjé N. Bumpus, Frances H. Priddy et al. · 2017 · AIDS and Behavior
94. Composite films for vaginal delivery of tenofovir disoproxil fumarate and emtricitabine
    Mafalda P. Cautela, Hen Moshe Halamish, Alejandro Sosnik, Bruno Filipe Carmelino Cardoso Sarmento, José das Neves · 2018 · European Journal of Pharmaceutics and Biopharmaceutics
95. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study)
    Ian McGowan, Ross Cranston, Kathryn Duffill, Aaron Siegel, Jarret C. Engstrom, Alexyi Nikiforov, Cindy E. Jacobson, Khaja K. Rehman, Julie E. Elliott, Elena Khanukhova et al. · 2015 · PLoS ONE
96. Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations
    Jennifer S. Gewandter, Robert H. Dworkin, Dennis C. Turk, Eric G. Devine, David Hewitt, Mark P. Jensen, Nathaniel P. Katz, Amy A. Kirkwood, Richard I. Malamut, John D. Markman et al. · 2019 · Journal of Pain
97. Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention
    Sai Archana Krovi, Leah M. Johnson, Ellen H. Luecke, Sharon L. Achilles, Ariane van der Straten · 2021 · Advanced Drug Delivery Reviews
98. Oral pre‐exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study
    Yunia Mayanja, Onesmus Kamacooko, Jane Frances Lunkuse, Vincent Muturi‐Kioi, Allan Buzibye, Denis Omali, Kundai Chinyenze, Monica O. Kuteesa, Pontiano Kaleebu, Matt A. Price · 2022 · Journal of the International AIDS Society
99. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations
    Catherine A. Koss, Peter Bacchetti, Sharon L. Hillier, Edward Livant, Howard Horng, Nyaradzo Mavis Mgodi, Brenda Gati Mirembe, Kailazarid Gomez, Stephanie Horn, Albert Liu et al. · 2017 · AIDS Research and Human Retroviruses
100. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen
     Monica Gandhi, Pamela M. Murnane, Peter Bacchetti, Richard Elion, Michael A. Kolber, Stephanie E. Cohen, Howard Horng, Alexander Louie, Karen Kuncze, Catherine A. Koss et al. · 2017 · AIDS